Upcoming Conferences for Apogee Therapeutics
Apogee Therapeutics, Inc. (Nasdaq: APGE), based in San Francisco and Boston, has exciting news for investors. The company's management team is gearing up to engage with investors at prominent upcoming healthcare conferences. These events will showcase their ongoing commitment to advancing healthcare innovation.
Conference Participation Details
Investors can look forward to several important presentations:
Guggenheim 2nd Annual Healthcare Innovation Conference
Scheduled for Tuesday, November 11, the fireside chat will commence at 1:30 p.m. ET. This platform will allow Apogee’s management to share insights into their research and development strategies.
Stifel 2025 Healthcare Conference
The following day, on November 12, at 11:20 a.m. ET, Apogee will have another opportunity to engage with investors during the Stifel conference.
TD Cowen Immunology and Inflammation Virtual Summit
On November 13, at 12:30 p.m. ET, Apogee will participate in this virtual summit focused on critical topics in immunology and inflammation.
Jefferies London Healthcare Conference
Moving to the international stage, Apogee will attend the Jefferies conference on November 19, where discussions will begin at 3:00 p.m. GMT / 10:00 a.m. ET. This conference provides a global platform to highlight innovations in biotechnology.
Citi 2025 Global Healthcare Conference
Lastly, on December 3, Apogee will round off the year with its presentation starting at 9:45 a.m. ET at the Citi Global Healthcare Conference, emphasizing its ongoing advancements.
Access to Webcast Information
For those unable to attend these events, a live and archived webcast of the discussions will be available on the News & Events section of the Apogee Therapeutics website. This ensures both investors and interested parties stay informed about the company’s trajectory and innovations.
About Apogee Therapeutics
Apogee Therapeutics is at the forefront of biotechnology, dedicated to developing groundbreaking biologics targeted at some of the largest inflammatory and immune diseases. Their research focuses on treating conditions such as Atopic Dermatitis (AD), asthma, and several other significant indications. The company’s lead antibody program, APG777, is making strides in treating AD, a field ripe for innovation due to the current market's limited solutions.
Apogee’s robust pipeline reflects their strategic commitment to not only addressing these critical health issues but also to enhancing patient care through novel treatment options that promise longer-lasting effectiveness and fewer side effects.
Investor Relations Contact Information
If you are an investor looking for more information, feel free to reach out to:
Investor Contact:
Noel Kurdi
VP, Investor Relations
Apogee Therapeutics, Inc.
noel.kurdi@apogeetherapeutics.com
Media Contact Information
For media inquiries, please contact:
Media Contact:
Dan Budwick
1AB
dan@1abmedia.com
Frequently Asked Questions
What is the purpose of the upcoming investor conferences?
The conferences will provide Apogee Therapeutics an opportunity to showcase their innovations and engage with investors about their latest developments.
When will Apogee Therapeutics present at the Guggenheim conference?
Apogee Therapeutics is scheduled to present at the Guggenheim 2nd Annual Healthcare Innovation Conference on November 11.
What advancements is Apogee Therapeutics focusing on?
Apogee is particularly focusing on developing biologics to treat inflamed and immune-related conditions, targeting major diseases like Atopic Dermatitis.
How can I access the conference webcasts?
Webcasts can be accessed live or archived on the Apogee Therapeutics website in the News & Events section.
Who should I contact for further investment inquiries?
For investment-related questions, you can contact Noel Kurdi, VP of Investor Relations at noel.kurdi@apogeetherapeutics.com.